Canada: Licensing & Syndication

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.

In a significant development for farmers and the agricultural industry, amendments made last year to the Canadian Copyright Act have introduced new exemptions...

On April 29, 2025, the United States Trade Representative (USTR) released its 2025 Special 301 Report. Each year, the USTR reports on the adequacy...

The rapid advancement of generative artificial intelligence ("AI") has ushered in a new era of innovation, but it has also raised significant legal and ethical questions, particularly concerning copyright infringement.

With the year well underway, it's an opportune time to examine the emerging and expected trends in 2025 for licensing partnerships in the life sciences industry.

For World IP Day 2025, we connected with members of our Trademarks & Copyright team for a short interview, reflecting on this year's theme from the World Intellectual Property Organization...

There's a new comeback story in town, and it's about as dramatic as a Snyder Cut reveal. Mattel has successfully clawed back the lucrative rights to make DC-themed action...

L'Office de la propriété intellectuelle du Canada (OPIC) a émis des alertes pour mettre le public en garde contre des demandes de paiement non sollicitées...

On April 29, 2025, the United States Trade Representative (USTR) released its 2025 Special 301 Report. Each year, the USTR reports on the adequacy...

In the first PMNOC decision of the year, Justice Furlanetto upheld the validity of claims 1 and 2 of Alexion's patent no. 2,645,810 which is directed to the antibody...